Filing excerpt
Letter Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026.
sec.gov/Archives/edgar/data/874716/000110465926003103/tm262817d1_8k.htmRead the full source
Idexx Laboratories8-K: Succession announcement
IDEXX Laboratories announces leadership transition involving CEO Jonathan Mazelsky and Michael Erickson, PhD.
What happened
The filing of letter agreements for both the current CEO and another executive, Michael Erickson, on the same day strongly indicates a planned leadership succession.
Source
Other signals in this filing (1)
- Governance changeIDEXX announces executive agreements with Michael Erickson and Jonathan Mazelsky dated Jan 12, 2026.Governance change
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Succession announcement
What this signalsFilings often name leadership changes, deals and spending plans.
- Form
- 8-K
- Filed
- Jan 13, 2026
More from Idexx Laboratories
- PatentsIDEXX LABORATORIES INC.'s patent output is slowing: 4 grants in the past year, 0 in the past 30 days.Patents
- GlassdoorEmployees report lack of merit-based pay progression despite competitive base salariesGlassdoor
- LaunchVeterinary Diagnostic Markets Report Now Available - See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030Launch
- Website changesIDEXX expanded its blog content toward practical, outcome-oriented guidance for veterinary practice owners and managers.Website changes
- LinkedInCompany seeks bilingual Inside Sales Associate to support Canadian veterinary practices with diagnostic solutions.LinkedIn
- 10-QG&A expenses jump 18.4% driven by technology and infrastructure investments10-Q
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 874716
- Accession number
- 0001104659-26-003103
- Timeframe
- Immediate
- Filing year
- 2026
- Why it matters
- Upcoming vendor review window
- Signal category
- Leadership
Extraction
- Confidence
- High
- Relevance
- 90%
- Sentiment
- Neutral
- Detected
- Feb 3, 2026
- signal_type
sec-8k- signal_subtype
successionAnnouncement
Use this data
Get every 8-K signal for Idexx Laboratories and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Idexx Laboratories this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/19bc8001-8bbb-4fa1-874a-0a5104c0458e returns this record as JSON. POST /v1/companies/enrich returns every signal for idexx.com.
{
"signal_id": "19bc8001-8bbb-4fa1-874a-0a5104c0458e",
"signal_type": "sec-8k",
"signal_subtype": "successionAnnouncement",
"detected_at": "2026-02-03T13:12:49.333+00:00",
"company": {
"name": "Idexx Laboratories",
"domain": "idexx.com"
},
"data": {
"detail": "The filing of letter agreements for both the current CEO and another executive, Michael Erickson, on the same day strongly indicates a planned leadership succession. Such transitions create significant opportunities as new leaders often re-evaluate strategic priorities, budgets, and key vendor relationships within the first 90-180 days.",
"metrics": {
"timeframe": "immediate"
},
"summary": "IDEXX Laboratories announces leadership transition involving CEO Jonathan Mazelsky and Michael Erickson, PhD.",
"excerpts": "Letter Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/874716/000110465926003103/tm262817d1_8k.htm",
"filing_date": "2026-01-13",
"filing_year": 2026,
"sales_relevance": "Upcoming vendor review window",
"signal_category": "leadership"
}
}
curl https://signals.autobound.ai/v1/signals/19bc8001-8bbb-4fa1-874a-0a5104c0458e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"idexx.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.